Article

Patient attitude towards lecanemab: results from a survey within the European Alzheimer’s disease consortium (EADC), the German memory clinic network (DNG) and Austrian memory centers

2025-06-17

Abstract excerpt

<h4>INTRODUCTION</h4> Lecanemab approval was long pending in the EU but has now been granted. European patient attitudes towards anti-amyloid therapies are insufficiently assessed and reported. <h4>METHODS</h4> We conducted an anonymous, multicenter survey across European memory clinics targeting patients with early symptomatic AD. A standardized questionnaire with four yes/no questions assessed attitudes toward l...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ed85930f-4b2f-5f28-b97b-ba2dcdfba349
DOI: 10.1101/2025.06.16.25329507

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Patient attitude towards lecanemab: results from a survey within the European Alzheimer’s disease consortium (EADC), the German memory clinic network (DNG) and Austrian memory centersDOI 10.1101/2025.06.16.25329507Read

Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain WestSemantic proximity Read

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read

Are Pre-frail and Frail Amyloid Positive Individuals Eligible to Lecanemab? A cross-sectional analysis from the Cogfrail Real-World CohortSemantic proximity Read

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read

Considerations regarding a diagnosis of Alzheimer’s Disease before dementia: a systematic reviewSemantic proximity Read

Lecanemab and APOE Genotyping in Clinical Practice-Navigating Uncharted Terrain.Semantic proximity Read

Reducing ARIA risk in Alzheimer's disease: Real-world impact of APOE genotype-guided slow titration with aducanumab and lecanemab.Semantic proximity Read

Public perceptions of presymptomatic testing for Alzheimer disease.Semantic proximity Read

Design and feasibility of an Alzheimer’s disease blood test study in a diverse community-based populationSemantic proximity Read

Participant attitudes toward returning individual results from CADASIL researchSemantic proximity Read

Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease ContinuumSemantic proximity Read

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.Semantic proximity Read